Open access · CC-BY
via OpenAlex
The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging
Farhad B. Imam, Rowan Saloner, Jacob W. Vogel, Varsha S. Krish, Gamal Abdel-Azim, Muhammad Ali, Lijun An, Federica Anastasi, David A. A Bennett, Alexa Pichet Binette, Adam L. Boxer, Martin Bringmann, Jeffrey Murray Burns, Carlos Cruchaga, Jeffrey L. Dage
Nature Medicine · 2025 · ▲ 130 citations
Abstract
More than 57 million people globally suffer from neurodegenerative diseases, a figure expected to double every 20 years. Despite this growing burden, there are currently no cures, and treatment options remain limited due to disease heterogeneity, prolonged preclinical and prodromal phases, poor understanding of disease mechanisms, and diagnostic challenges. Identifying novel biomarkers is crucial for improving early detection, prognosis, staging and subtyping of these conditions. High-dimensional molecular studies in biofluids ('omics') offer promise for scalable biomarker discovery, but challenges in assembling large, diverse datasets hinder progress. To address this, the Global Neurodegeneration Proteomics Consortium (GNPC)-a public-private partnership-established one of the world's largest harmonized proteomic datasets. It includes approximately 250 million unique protein measurements from multiple platforms from more than 35,000 biofluid samples (plasma, serum and cerebrospinal fluid) contributed by 23 partners, alongside associated clinical data spanning Alzheimer's disease (AD), Parkinson's disease (PD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). This dataset is accessible to GNPC members via the Alzheimer's Disease Data Initiative's AD Workbench, a secure cloud-based environment, and will be available to the wider research community on 15 July 2025. Here we present summary analyses of the plasma proteome revealing disease-specific differential protein abundance and transdiagnostic proteomic signatures of clinical severity. Furthermore, we describe a robust plasma proteomic signature of APOE ε4 carriership, reproducible across AD, PD, FTD and ALS, as well as distinct patterns of organ aging across these conditions. This work demonstrates the power of international collaboration, data sharing and open science to accelerate discovery in neurodegeneration research.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1038/s41591-025-03834-0
- Canonical
- link ↗
- Fetched
- 2026-10-17 MST
Cite this
APA
Imam, F.B., Saloner, R., Vogel, J.W., Krish, V.S., Abdel-Azim, G., Ali, M., An, L., Anastasi, F., Bennett, D.A.A., Binette, A.P., Boxer, A.L., Bringmann, M., Burns, J.M., Cruchaga, C., Dage, J.L., Farinas, A., Ferrucci, L., Finney, C.A., Frasier, M.A., & Hansson, O. (2025). The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging. <em>Nature Medicine</em>. https://doi.org/10.1038/s41591-025-03834-0
Vancouver
Imam FB, Saloner R, Vogel JW, Krish VS, Abdel-Azim G, Ali M, et al. The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging. Nature Medicine. 2025. doi:10.1038/s41591-025-03834-0.
BibTeX
@article{farhad2025TheGlo,
title = {The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging},
author = {Farhad B. Imam and Rowan Saloner and Jacob W. Vogel and Varsha S. Krish and Gamal Abdel-Azim and Muhammad Ali and Lijun An and Federica Anastasi and David A. A Bennett and Alexa Pichet Binette and Adam L. Boxer and Martin Bringmann and Jeffrey Murray Burns and Carlos Cruchaga and Jeffrey L. Dage and Amelia Farinas and Luigi Ferrucci and Caitlin A. Finney and Mark A. Frasier and Oskar Hansson and Timothy J. Hohman and Erik C. B. Johnson and Mika Kivimaki B and Roxanna Korologou‐Linden and Agustı́n Ruiz},
journal = {Nature Medicine},
year = {2025},
doi = {10.1038/s41591-025-03834-0},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
bioRxiv (Cold Spring Harbor Laboratory) 2026
Preprint · CC-BY
Proteome-aware organ proxy aging clocks
Frontiers in aging neuroscience 2026
Citation only
Global research trends and hotspots in blood-based biomarkers for Alzheimer's disease: a bibliometric analysis.
Aging Cell 2024
Open access · CC-BY
Proteomic aging clock ( PAC ) predicts age‐related outcomes in middle‐aged and older adults
medRxiv 2025
Preprint · CC-BY
Multi-organ MRI digitizes biological aging clocks across proteomics, metabolomics, and genetics
Molecular Neurodegeneration 2015
Open access · CC-BY
Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay
Nature Communications 2026
Open access · CC-BY